SCHEMBL6508786

SCHEMBL6508786

O=[N+]([O-])c1cc(Br)[n+]([O-])cc1Br

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.40
CYP3A4 P08684 1/20 0.40
CA12 O43570 2/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA9 Q16790 2/20 0.38
MAPT P10636 4/20 0.38
CYP2D6 P10635 1/20 0.38
VCAM1 P19320 1/20 0.37
CYP1A2 P05177 1/20 0.36
CTSB P07858 1/20 0.36
PKM P14618 1/20 0.36
MAPK1 P28482 1/20 0.35
KDM4E B2RXH2 2/20 0.34
NPC1 O15118 1/20 0.34
S1PR4 O95977 1/20 0.34
S1PR1 P21453 1/20 0.34
HTT P42858 1/20 0.34
RAB9A P51151 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL928995 0.81 MAPT (0.46) ALDH1A1CYP3A4MAPTCYP2D6CYP1A2
SCHEMBL28980003 0.81 VCAM1 (0.39) ALDH1A1CYP3A4MAPTCYP2D6VCAM1
SCHEMBL2596740 0.81 CYP1A2 (0.46) ALDH1A1CYP3A4MAPTCYP1A2KDM4E
SCHEMBL26077511 0.81 VCAM1 (0.46) ALDH1A1CYP3A4VCAM1CYP1A2MAPK1
SCHEMBL1338960 0.81 VCAM1 (0.44) ALDH1A1CYP3A4CA12CA1CA2
SCHEMBL29546613 0.81 VCAM1 (0.44) ALDH1A1CYP3A4CA12CA1CA2
SCHEMBL10330659 0.77 MAPT (0.36) ALDH1A1CYP3A4MAPTCYP2D6VCAM1
SCHEMBL1338313 0.77 HCAR3 (0.43) ALDH1A1MAPTCYP1A2PKMMAPK1
SCHEMBL19616214 0.77 ALDH1A1 (0.43) ALDH1A1CYP3A4MAPTCYP1A2MAPK1
SCHEMBL16428099 0.73 HCAR3 (0.50) ALDH1A1MAPTCYP1A2PKMMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9675593-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2017-06-13 US disclosed
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2017-05-04 US disclosed
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2016-09-15 US disclosed
US-9359379-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2016-06-07 US disclosed
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2014-04-17 US disclosed
WO-2005003103-A2 2, 4, 6-TRI-SUBSTITUTED 6-MEMBERED HETEROCYCLES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES ASTRAZENECA AB (SE) 2005-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 ALDH1A1 529/4885CYP3A4 4025/4885CA12 4778/4885
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 ALDH1A1 529/4885CYP3A4 4025/4885CA12 4778/4885
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 ALDH1A1 529/4885CYP3A4 4025/4885CA12 4778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.